Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537868 | 0.88 | NOTUM (0.50) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL223608 | 0.79 | MEN1 (0.54) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL2319502 | 0.79 | MEN1 (0.50) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL782147 | 0.79 | MEN1 (0.50) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL11804991 | 0.79 | MEN1 (0.50) | ALDH1A1MEN1KMT2AMAPTGAA | |
| Methane SCHEMBL11307340 | 0.78 | MEN1 (0.49) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL2596389 | 0.76 | MEN1 (0.51) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL28545524 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL16328733 | 0.73 | MEN1 (0.52) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL20456233 | 0.73 | MEN1 (0.49) | ALDH1A1MEN1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103313989-A | Tricyclic PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | claimed |
| US-20240239843-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-107921030-B | Covalent linker of antibody-drug conjugate, preparation method and application thereof | 荣昌生物制药(烟台)股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-114939174-B | Covalent linker of antibody-drug conjugate, preparation method and application thereof | 荣昌生物制药(烟台)股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118265720-A | Compositions and methods for treating metabolic disorders and liver diseases | 维京治疗公司 | 2024-06-28 | — | — | CN | disclosed |
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | QPEX BIOPHARMA, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-118251218-A | Combination therapy for treating cancer using PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240197750-A1 | CEFTIBUTEN DOSING REGIMENS | QPEX BIOPHARMA INC (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024124279-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CERTA THERAPEUTICS PTY LTD (AU) | 2024-06-20 | — | — | WO | disclosed |
| EP-3781576-B1 | BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF | QPEX BIOPHARMA INC (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2006060494-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
| EP-1664003-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1663958-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006034004-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-18 | — | — | US | disclosed |
| WO-2005058348-A1 | USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005028454-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005028429-A2 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016868-B2 | Boronic acid derivatives and therapeutic uses thereof | BCL6B, BCL6, BTD | ALDH1A1 1981/4885MEN1 608/4885KMT2A 3882/4885 |
| US-20240197750-A1 | CEFTIBUTEN DOSING REGIMENS | PEPD, NQO1, BTD | ALDH1A1 3339/4885MEN1 4459/4885KMT2A 1775/4885 |
| US-20240239843-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISORDERS | GIPR, GLP1R, GPR119 | ALDH1A1 2792/4885MEN1 1218/4885KMT2A 3614/4885 |
| US-20050182096-A1 | Haloalkyl containing compounds as cysteine protease inhibitors | CTSF, CTSS, CTSE | ALDH1A1 1944/4885MEN1 4684/4885KMT2A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.